Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuadrise Regulatory News (QED)

Share Price Information for Quadrise (QED)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.00 (0.00%)
Bid:
2.00
Ask:
2.19
Spread: 0.19 (9.50%)
Market Cap: £44.34m
QED Live PriceLast checked at - London Stock Exchange

Intraday Quadrise Share Chart

Project Agreement with MSC and Cargill

26 Nov 2024 07:00

RNS Number : 5867N
Quadrise PLC
26 November 2024
 

26 November 2024

 

Quadrise Plc ("Quadrise" or the "Company")

 

Collaboration and Operational Trial Agreement with MSC and Cargill

 

Quadrise Plc (AIM: QED), the supplier of innovative energy solutions for a cleaner planet, is delighted to announce the signature of a Collaboration and Operational Trial Agreement (the "Project Agreement") with MSC Shipmanagement Ltd ("MSC") and Cargill NV ("Cargill"), paving the way for the long-awaited vessel trials on board the MSC Leandra (the "Trials").

 

Further to the Company's announcement of 10 July 2024, and under the Project Agreement, Quadrise, MSC and Cargill have agreed their respective obligations under which the Company's fuels, bioMSAR™ and MSAR®, will be produced at the MAC2 facility in Antwerp, Belgium using feedstocks supplied by Cargill and then sold by Cargill to MSC for the Trials.

 

The parties to the Project Agreement will use their reasonable endeavours to contribute towards the successful Trials and to receipt of a final Letter of No Objection from Wärtsilä following 4,000 hours of bioMSAR™ testing, with:

· Quadrise providing equipment, additives and technical expertise; and

· MSC providing the trial vessel, MSC Leandra, necessary flag state approvals for the Trials and procuring professional monitoring services for the Trials; and

· Cargill providing the necessary feedstocks, transportation of fuels and operational and logistical support.

 

MAC2 have already received the required operating permits for installation of Quadrise equipment and have prepared the site. Following signature of the Project Agreement, final work to enable Quadrise equipment to be delivered to the MAC2 site can now be completed, enabling the Trials to commence before end Q1 2025.

 

In parallel, bilateral agreements, including a toll manufacturing agreement between Cargill and Quadrise in respect of fuel manufacture, can be finalised now that the outline commercial terms have been agreed in the Project Agreement.

 

Upon successful conclusion of the Trials, MSC, Cargill and Quadrise will negotiate and enter into a definitive long-term Commercial Agreement.

 

The Project Agreement will expire on the sooner of: (1) One year following completion of the Trials; (2) Commencement of a Commercial Agreement.

 

Commenting on this agreement Jason Miles, CEO of Quadrise, said:

"Quadrise is delighted to have signed this pivotal agreement with MSC and Cargill, which triggers the process for the trials to get underway. We are hugely excited to be partnering with world-leading Companies to demonstrate the commercial viability and environmental benefits of our technology and the contribution it can make to decarbonisation of the shipping sector. Having already successfully demonstrated MSAR® on the trial vessel, we are highly confident of a successful trial result on bioMSAR™ and the substantial commercial opportunities that this will lead to."

 

 About the MSC Vessel Trials

 

The Trials will be carried out on the MSC Leandra, previously used for prior successful MSAR® demonstrations, following the installation and commissioning of Quadrise equipment at the MAC2 facility in Antwerp, Belgium and are expected to commence before end Q1 2025.

 

The Trials will commence with Proof of Concept ('POC') tests using MSAR® and bioMSAR™. Each POC Trial is estimated to require around 1,000 metric tons ("MT") of fuel to confirm engine performance on the vessel.

 

Subject to positive results from the POC Trials, the fuels will undergo subsequent trials to provide commercial operating experience with a view to obtaining Letters of No Objection ("LONOs") from the engine manufacturer after confirming the operational viability of bioMSAR™ and MSAR® at both an interim (midway) and final stage (after circa 4,000 operating hours). During the LONOs it is planned that barge deliveries of up to 1,500MT of Quadrise fuels will be supplied to the MSC vessel every 4-6 weeks for the Trials, over a period of 6-8 months.

 

Upon completion of the Trials and receipt of the LONO, or when sufficient progress has been demonstrated to the satisfaction of MSC, Cargill and Quadrise (the "Parties"), the Parties plan to conclude long-term commercial agreements within three months of achieving this milestone. 

 

Additionally, MSC and Quadrise will continue discussions with other marine engine suppliers to investigate testing bioMSAR™ and MSAR® on their engines and will also explore opportunities to test the Quadrise Blend-on-Board solution which will open up new possibilities for tramping vessels and provide additional flexibility on bioMSAR™ supply.

 

 

For additional information, please contact:

 

Quadrise Plc

+44 (0)20 7031 7321

Andy Morrison, Chairman

Jason Miles, Chief Executive Officer

Nominated Adviser

Cavendish Capital Markets Limited

+44 (0)20 7220 0500

Ben Jeynes

Katy Birkin

George Lawson

Joint Brokers

Shore Capital Stockbrokers Limited

Toby Gibbs, Rachel Goldstein (Corporate Advisory)

Fiona Conroy (Corporate Broking)

+44 (0)20 7408 4090

 

VSA Capital Limited

Andrew Raca (Corporate Finance)

Andrew Monk (Corporate Broking)

 

+44 (0)20 3005 5000

 

Public & Investor Relations

 

 

Cutbill Jacoby

Andy Cutbill

Frankie Dundon

 

+44 (0)7841 576000

+44 (0)7312 274086

 

About Quadrise:

Quadrise is the supplier of MSAR® and bioMSAR™ emulsion technology, fuels and biofuels, providing innovative solutions to lower energy costs, pollution and greenhouse gas emissions today for the global power generation, shipping, industrial and oil industries.

Learn more at: www.quadrise.com

 

Follow us on social media:

LinkedIn: @Quadrise Plc

X (formerly Twitter): @QuadrisePlc

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR") and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRBABPTMTATBPI
Date   Source Headline
15th Apr 20267:00 amRNSDirectorate change
23rd Mar 20267:00 amRNSInterim Results & Notice of Investor Presentation
19th Mar 20267:00 amRNSAppointment of Non-Executive Director
3rd Feb 20267:00 amRNS-RPublication of 2025 Sustainability Report
12th Jan 20267:00 amRNSExtension of Exclusive Agreement with Nouryon
9th Jan 20267:00 amRNSDirector/PDMR Shareholding and Directorate Change
4th Dec 202512:17 pmRNSDirector/PDMR Shareholding
28th Nov 20252:55 pmRNSResult of AGM
28th Nov 20257:00 amRNSAGM Statement
7th Nov 20253:01 pmRNSDirector/PDMR Shareholding
6th Nov 20251:46 pmRNSDirector/PDMR Shareholding
28th Oct 20255:23 pmRNSPosting of Annual Report and Notice of AGM
27th Oct 20257:00 amRNSIssue of Options and Director Dealing
13th Oct 20257:00 amRNSIssue of Share Options and Director/PDMR Dealing
29th Sep 20257:00 amRNSFinal Results and Notice of AGM
26th Sep 20257:00 amRNSValkor update
17th Sep 20257:00 amRNSSuccessful Sparkle Power Programme Testing
15th Sep 20257:00 amRNSCEO Appointment
18th Aug 20257:00 amRNSBusiness Update
25th Jul 20257:00 amRNSDirector / PDMR Shareholding
14th Jul 20258:00 amRNSDirector/PDMR Shareholding
4th Jul 202511:50 amRNSExercise of Options and Total Voting Rights
17th Jun 20257:00 amRNSJoint Development Agreement with Alder Energy LLC
10th Jun 20257:00 amRNSBusiness Update
23rd May 20257:00 amRNSExercise of Warrants
1st May 20257:01 amRNSTotal Voting Rights
1st May 20257:00 amRNSManagement Update
3rd Apr 20257:00 amRNSExercise of Share Options
1st Apr 20257:00 amRNSMAC2 Services Agreement
26th Mar 202512:46 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSLicella Joint Development Agreement
24th Mar 20257:00 amRNSInterim Results and Investor Presentation
13th Mar 20257:00 amRNS-RAppointment of Head of Marine
31st Jan 20257:00 amRNSResult of Retail Offer
30th Jan 20252:36 pmRNSIncrease of Retail Offer
28th Jan 20257:00 amRNSAppointment of Director
24th Jan 202510:04 amRNSRetail Offer - Notice of IMC Presentation
24th Jan 20257:05 amRNSRetail Offer
24th Jan 20257:00 amRNSResult of Placing and Subscription
23rd Jan 20254:51 pmRNSProposed Placing, Subscription and Retail Offer
15th Jan 20257:00 amRNSValkor License Revenues
16th Dec 20247:00 amRNSMaterial Transfer Agreement with Sparkle Power SA
5th Dec 20247:00 amRNS-RbioMSAR™ Development Update
26th Nov 20247:00 amRNSProject Agreement with MSC and Cargill
25th Nov 20247:00 amRNSCollaboration Agreement with Auramarine
22nd Nov 20244:57 pmRNSResult of AGM
22nd Nov 20247:00 amRNSAGM Statement
25th Oct 20244:05 pmRNSPosting of Annual Report & Notice of AGM
30th Sep 20247:00 amRNSFinal Results and Notice of AGM
2nd Aug 20247:00 amRNSIssue of Share Options and Director/PDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.